Jasper Therapeutics has reported updated clinical data showing disease control in patients treated with briquilimab for chronic spontaneous urticaria. The results support dose selection for a planned Phase 2b study later in 2026.
Briquilimab efficacy observed in BEACON study
The updated data come from the Phase 1b/2a BEACON study evaluating subcutaneous briquilimab in adults with moderate to severe chronic spontaneous urticaria. Patients enrolled had persistent symptoms despite high-dose antihistamine treatment.
Importantly, among additional participants treated in the 240 mg / 180 mg every-eight-week cohort, the mean reduction in UAS7 score was 31 points at 12 weeks. Complete response was reported by 67% of treated patients at week 12.
Open-label extension shows sustained disease control
In addition, Jasper reported results from an open-label extension study including patients with chronic spontaneous and chronic inducible urticaria. All participants received briquilimab at a dose of 180 mg every eight weeks.
At 12 weeks, 58% of chronic spontaneous urticaria patients achieved complete response, while 75% achieved either complete response or well-controlled disease. Among chronic inducible urticaria participants, 65% achieved complete or partial response at 16 weeks.
Safety profile consistent across studies
Meanwhile, safety outcomes remained consistent across both studies, with no dose-limiting toxicities observed. Adverse events potentially related to KIT inhibition were infrequent, predominantly low grade, and generally resolved during ongoing treatment.
The median follow-up duration exceeded 200 days across 63 participants, supporting continued evaluation of briquilimab in later-stage clinical development.
Phase 2b study planned for second half of 2026
As a result of the combined data from the BEACON and open-label extension studies, Jasper Therapeutics confirmed that dose selection is now complete. The company plans to initiate a Phase 2b study of briquilimab in chronic spontaneous urticaria in the second half of 2026.
Further information about the company is available on the Jasper Therapeutics website. Related coverage can be found in the Life Sciences Global News Pharmaceuticals section.
